Turoktokog alfa
Klassificering: BATC kod: B02BD02
Sammanfattning
Eftersom substansen nästan bara används av män har analys avseende könsskillnader inte bedömts relevant.
Additional information
Tuructocog alfa is a factor VIII concentrate product used in treatment of acute bleeding episodes, perioperative management and routine prophylaxis patients with hemophilia A [1]. Hemophilia A (deficiency in coagulation factor VIII) is an inherited X-linked disease and thus affects primarily men although women also can be affected (for example because of skewed inactivation of chromosome X) [2]. The occurrence of hemophilia A in women is very rare and data in women is not available [3].
Pharmacokinetics and dosing
No studies with a clinically relevant sex analysis regarding pharmacokinetics and dosing of tuructocog alfa have been found.
Effects
No studies with a clinically relevant sex analysis regarding effects of tuructocog alfa have been found.
Adverse effects
No studies with a clinically relevant sex analysis regarding adverse effects of tuructocog alfa have been found.
Reproductive health issues
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Försäljning på recept
Nästan enbart män hämtade ut läkemedel innehållande koagulationsfaktor VIII (ATC-kod B02BD02) på recept i Sverige år 2019, totalt 430 män och 4 kvinnor [4].
Uppdaterat: 2021-06-07
Litteratursökningsdatum: 2020-05-20
Referenser
- Vakil NH, Fujinami N, Martin-Stone S. Turoctocog alfa for the treatment of hemophilia a. Pharmacotherapy. 2014;34(10):1091-101. PubMed
- Mehta P and Reddivari AKR. Hemophilia, in StatPearls. Treasure Island (FL): StatPearls Publishing; 2021.
- NovoEight (turoctocog alfa). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2020-03-12, cited 2020-05-20].
- Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.] länk
Faktagranskat av: Carl-Olav Stiller, Diana Rydberg
Godkänt av: Karin Schenck-Gustafsson